<DOC>
	<DOCNO>NCT01938924</DOCNO>
	<brief_summary>A study investigate gekoTM device improve flow vascular bypass graft</brief_summary>
	<brief_title>Surgical Revascularisation Nerve Stimulation Trial</brief_title>
	<detailed_description>The geko™ device , ( CE 558928 ; British Standards Institute notify body 0086 ) , wearable , discrete , self-contained stimulation unit adhere skin ( see www.gekodevices.com ) . The , geko™ produce small electrical impulse gently activate common peroneal nerve within popliteal fossa , behind knee , turn activate venous muscle pump calf foot . Substantive increase low limb blood flow demonstrate improve arterial , venous microcirculatory blood flow report morbidity . RATIONALE Early infra-inguinal graft failure , i.e . occur within 30 day surgery occur approximately 5 % patients16 . It know predominant cause thrombosis . The geko™ electrical device place common peroneal nerve alongside knee . The device activate muscle contraction peronei use low intensity , low frequency ( 1Hz ) stimulation . The muscle contraction express blood deep venous system . Application stimulation device peroneal nerve suitable practical purpose . Previous study show geko™ substantively increase arterial , venous microcirculatory blood flow healthy volunteer . A significant decrease Tissue Plasminogen Activator antigen also demonstrate indicates increase fibrinolytic activity3 . Application geko™ device therefore decrease stasis increase flow though graft reduce risk thrombosis graft failure . Study : Environmental Conditions The examination carry designated temperature control clinical room Vascular Lab Hull Royal Infirmary . Participants require abstain vigorous exercise , nicotine , caffeine fatty food prior examination . They require wear light garment leg expose . The geko™ device apply outer/ posterior aspect knee whilst subject semi-recumbent , knee flex . The participant give 30 minute quiet , environmentally control room prior commencement measurement enable equilibration . Assessments Participants complete McGill Pain questionnaire prior device activation Participants geko™ device apply whilst semi-recumbent knee flex . The intensity increase visible muscle stimulation evident ( concentric isotonic contraction ) patient tolerance reach - Laser Doppler image use assess microcirculation flow dorsum foot : 1 . Baseline ( rest ) 2 . 5 minute interval geko™ device active 3 . 30 minute follow removal device Laser Doppler flowmetry reproducible , objective , non-invasive measurement use evaluate real time cutaneous blood flow . The low power light conduct via glass fibre probe attach skin scatter movement blood cell induce Doppler shift . This allow information flux cell velocity record . The system use trial Moor Instruments DT-4 main unit integrated bilateral laser . - Ultrasound Doppler arterial flow velocity blood volume flow within femoral artery ( mid thigh ) bilaterally : 1 . Baseline ( rest ) 2 . 30 minute device active - Ultrasound Doppler flow velocity femoral vein ( mid thigh ) bilaterally : 1 . Baseline ( rest ) 2 . 40 minute geko active - Vicorder measurement arterial stiffness , pulse wave velocity stroke volume : 1 . Baseline ( rest ) 2 . Immediately follow removal/ deactivation device - Vascular Endothelial Growth Factor ( VEGF ) , Tissue Plasminogen Activator antigen ( TPA antigen ) , Full blood count ( FBC ) Plasminogen activator inhibitor-1 ( PAI-1 ) : 15 ml blood take femoral vein : 1 . Baseline ( rest ) 2 . 45 minute geko™ device active ELISA analysis carry sample ( see appendix ) . Vascular Endothelial Growth Factor - Therapies lead development new , collateral blood vessel , particular interest field peripheral arterial disease narrow blockage exist blood vessel result tissue ischaemia . Vascular endothelial growth factor ( VEGF ) signal protein produce cell stimulate growth new blood vessel pre-existing vessel . Several previous study show electrical stimulation increase VEGF level turn increase vessel density muscle . Tissue plasminogen activator ( tPA ) protein involve breakdown blood clot . As result therapeutic us clinical medicine treat thromboses emboli . Electrical stimulation previously show provoke acute release tPA circulation , although appear response decrease repeat stimulation . Use geko™ device show result significant decrease Tissue Plasminogen Activator ( tPA ) antigen indicative increase fibrinolytic activity . Plasminogen activator inhibitor- 1 ( PAI-1 ) primary inhibitor plasminogen activator inactivate tissue plasminogen activator ( t-PA ) urokinase-type plasminogen activator ( u-PA ) . PAI-1 important inhibitor fibrinolytic system , elevate level could suppress fibrinolysis result increase risk thrombosis . Increased PAI-1 level show associated number atherosclerotic risk factor , PAI-1 show act prothrombic factor arterial venous thromboembolic disorder . - Ankle Brachial Pressure Index baseline post removal geko™- utilising Posterior Tibial Artery Anterior Tibial Artery - Maximum calf circumference baseline post removal geko™ - Three blood pressure heart rate measurement take bilaterally baseline @ 30 minute device active . The mean three value use comparison . - Patient tolerance/ acceptability + Nurse tolerance/ ease application Questionnaire use Visual Analogue Scores Verbal Rating Scores complete follow removal geko™ device ( see appendix ) - The McGill Pain Questionnaire complete follow device removal</detailed_description>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>1 . Age ≥18 year , 2 . Undergoing infrainguinal vein bypass graft . 3 . Intact cutaneous sensation nociception lower limb , determine investigator . 4 . Intact healthy skin site application . 5 . On effective contraception sexually active oral contraceptive pill ( &gt; 3 month use ) , condom , intrauterine contraceptive device , depot injection . 6 . Able understand Patient Information Sheet capable willing give inform consent follow protocol requirement 1 . History haematological disorder DVT within precede 6 month , 2 . Pregnant plan become pregnant study duration , 3 . Pacemakers implantable defibrillator , 4 . Use neuromodulation device , 5 . Current use TENS pelvic region , back leg , 6 . Use investigational drug/device therapy within past 4 week may interfere study , 7 . Significant varicose vein low limb ulceration . 8 . Recent surgery ( abdominal , gynaecological , hip knee replacement ) . 9 . Recent trauma lower limb . 10 . Chronic Obesity ( BMI Index &gt; 34 ) . 11 . Any medication judge significant Principal Investigator . 12 . Any significant illness four ( 4 ) week precede screen period study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>